secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001655759-24-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q4/FY2023: revenue down 40% to $78.5M; CFO resigns, vepdegestrant Fast Track
--------------------------------------------------------------------------------

- FY2023 revenue $78.5M vs $131.4M prior; Q4 revenue negative $43.1M. R&D expense $379.7M. Cash $1.27B, sufficient into 2027.
- Vepdegestrant: FDA Fast Track; Phase 1b combo with palbociclib CBR 63%, ORR 42%, median PFS 11.1 months. Phase 3 VERITAC-2 enrollment on track for 2H 2024.
- AR program: ARV-766 selected as lead; new Phase 1/2 data showed broader efficacy vs bavdegalutamide. Phase 2 PFS data mid-2024; regulatory discussions for Phase 3 in mCRPC Q2 2024.
- CFO Sean Cassidy resigns effective Feb 29; interim CFO Randy Teel. Board launched permanent replacement search.
- Closed $350M oversubscribed private placement; new Pfizer collaboration for E3 ligases. Regulatory clearance for ARV-102 (LRRK2) and ARV-393 (BCL6) Phase 1 trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000014/0001655759-24-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000014/arvn-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer